December 20, 2021 -- Denovo Biopharma announced that it has discovered a novel genetic biomarker, which it is calling Denovo Genomic Marker 7 (DGM7), using its biomarker discovery platform.
DGM7 has been shown to be associated with a response to treatment in recurrent high-grade glioma (HGG) with an investigational gene therapy combination treatment, DB107, via retrospective analysis. In addition to its potential benefit for patients who respond to DB107 therapy, DGM7 may extend to the broader retroviral replicating vector (RRV) platform, said the firm.
DB107 utilizes the RRV gene therapy platform combined with a prodrug to selectively infect and kill cancer cells while stimulating a robust anti-cancer immune response against a tumor with minimal toxicity, according to Denovo.
The most common type of HGG is glioblastoma multiforme (GBM), which is also the most common type of adult primary malignant brain cancer. Each year, 18,000 individuals in the U.S. are diagnosed with HGG and 13,000 die. The five-year survival rate for patients with GBM is less than 5%.
Copyright © 2021 scienceboard.net